What does Cypherpunk Technologies do?
Cypherpunk Technologies Inc. is a Nasdaq Capital Market company combining a concentrated Zcash treasury with privacy-technology investments. Formerly Leap Therapeutics, it still owns the oncology business through a wholly owned subsidiary. Most balance-sheet value now depends on ZEC, while the drug portfolio retains scientific and partnering optionality.
Which activities define the company today?
How should researchers classify it?
Cypherpunk is best understood as a privacy-focused treasury and investment vehicle with a biotechnology subsidiary, not as a conventional software company. The Q1 2026 Form 10-Q reports one operating and reportable segment at the consolidated level. The strategic pillars are economically distinct despite the single-segment presentation.
| Identity item | Current position | Analytical implication |
|---|---|---|
| Official name and ticker | Cypherpunk Technologies Inc. (CYPH) | The name and symbol changed in November 2025 after the strategy pivot. |
| Exchange | Nasdaq Capital Market | The company regained minimum-bid compliance in May 2026; future listing compliance remains relevant. |
| Economic exposure | ZEC price, privacy-tech investments, oncology assets | Reported earnings and net asset value can move for very different reasons. |
| Revenue status | No product revenue | Traditional revenue multiples and mature-company DCF methods are weak starting points. |
How does Cypherpunk make money?
Cypherpunk has no recurring operating-revenue engine. Its biotechnology products are unapproved and have generated no product-sales revenue. Value instead comes from ZEC price changes, privacy-technology investments, financing activity, and potential licensing or commercialization of Leap assets.
Why is the treasury model different from an operating business?
Accounting income can diverge sharply from cash generation. A rising ZEC price creates unrealized gains without cash receipts; a decline can create a large net loss despite falling operating expenses. The 2025 Form 10-K is therefore mainly a balance-sheet and capital-allocation document.
Which source of value matters most?
The asset mix makes the answer clear: ZEC is the dominant current economic exposure. The biotechnology portfolio matters as a potentially asymmetric option, but it does not currently produce revenue and consumed only $0.161 million of R&D expense in Q1 2026 after the 2025 wind-down.
How did a biotechnology company become a Zcash treasury company?
Cypherpunk’s balance sheet and governance were rebuilt rapidly. The pivot followed oncology cost reductions, a large private placement, and the arrival of digital-asset investors and directors.
Which turning points still shape the company?
-
2011The company was incorporated in Delaware and developed around biomarker-targeted oncology programs. That legacy explains the continuing sirexatamab and FL-501 assets.
-
2023Leap combined with Flame Biosciences, adding assets and organizational complexity to the biotechnology platform.
-
June 2025The board completed the DeFianCe trial, wound down major R&D activity, and reduced the workforce by approximately 75%, materially lowering the cash-burn profile.
-
October 2025A private placement generated $58.888M of gross proceeds and $57.170M of net proceeds. Winklevoss Treasury Investments became the lead investor.
-
November 2025The company renamed itself Cypherpunk Technologies, changed its Nasdaq symbol from LPTX to CYPH, and disclosed an initial 203,775.27 ZEC position acquired for about $50M.
-
December 2025Treasury holdings reached 290,062.67 ZEC after another $29M purchase, making ZEC the central balance-sheet asset.
-
March–May 2026Cypherpunk invested $5M in ZODL, increased holdings to 314,185.70 ZEC, and Leap received FDA Fast Track designation for sirexatamab in a DKK1-high colorectal-cancer setting.
The decisive event was the October 2025 financing and governance realignment. The November 12, 2025 Form 8-K documented the new name, ZEC strategy, board appointments, executive incentives, and creation of the Leap subsidiary. From that point, capital allocation moved from primarily funding clinical development to building a concentrated privacy-asset treasury.
What does Cypherpunk’s latest quarter show?
Q1 2026 shows why net income is misleading. Cypherpunk recorded a $77.166 million net loss, driven by a $77.555 million unrealized ZEC decline as the token price fell from $508.09 to $240.47. The operating loss was only $4.817 million.
| Q1 metric | Three months ended March 31, 2026 | Three months ended March 31, 2025 | Interpretation |
|---|---|---|---|
| R&D expense | $0.161M | $12.911M | Clinical-trial completion and the workforce reduction sharply lowered biotech spending. |
| G&A expense | $4.656M | $3.006M | Higher stock-based compensation and public-company costs offset R&D savings. |
| Operating loss | $(4.817)M | $(15.917)M | Underlying quarterly cash-cost structure improved substantially. |
| Unrealized ZEC fair-value change | $(77.555)M | Not applicable | Token-price movement dominated reported earnings. |
| Net loss | $(77.166)M | $(15.435)M | Accounting volatility was far larger than operating expense. |
| Basic and diluted loss per share | $(0.46) | $(0.37) | The share count also expanded materially after the 2025 financing. |
What changed in the cost structure?
What does the balance sheet say?
The official Q1 2026 results release also showed $6.689 million of cash, $81.922 million of current assets, and 93,927,528 common shares outstanding at quarter-end. Low liabilities provide flexibility, but liquidity outside ZEC is limited.
Why is ZEC concentration the core strategic bet?
Cypherpunk is deliberately concentrated in Zcash, a privacy network using zero-knowledge proofs for shielded transactions. Management targets at least 5% of circulating supply over time, subject to revision or suspension.
Purchases accelerated quickly: 203,775.27 ZEC cost about $50 million at $245.37; another 29,869.29 ZEC cost $18 million at $602.63; and 56,418.09 ZEC cost about $29 million at $514.02. See the November 18 acquisition announcement and the December 30 treasury update.
How far is Cypherpunk from its stated network target?
Why does the ZODL investment matter?
The $5.0 million ZODL investment extends the thesis into ecosystem development. Better wallet usability could support Zcash adoption and benefit both holdings. However, ZODL remains tied to the same ecosystem, adding strategic depth but little diversification.
What gives Cypherpunk a competitive position?
Cypherpunk lacks a conventional moat based on customers or switching costs. Its position comes from early ZEC concentration, crypto-native investors, public-market financing access, and a privacy-focused mandate.
Where can the company differentiate?
| Strategic resource | Evidence | Potential advantage | Constraint |
|---|---|---|---|
| Large ZEC position | 314,185.70 ZEC; 1.88% of circulating supply at May 13, 2026 | Meaningful sensitivity to network appreciation and visibility within the ecosystem | Extreme concentration and price volatility |
| Investor network | Winklevoss-linked lead investment and board rights | Crypto-market knowledge, financing relationships, and sourcing credibility | Related-party and governance dependence |
| Public listing | Nasdaq-listed equity and active shelf/ATM capacity | Can raise capital to accumulate assets or fund investments | Dilution and minimum-bid compliance risk |
| Biotech option | Sirexatamab Fast Track designation and DKK1 biomarker data | Potential partnering or development value outside digital assets | No approved product, no product revenue, and limited current R&D spending |
Who competes with this model?
Competitors include other digital-asset treasury firms, exchange-traded products, crypto funds, privacy-focused venture investors, and oncology developers. Cypherpunk has no operating market share to defend; it must prove that its corporate structure adds value beyond direct ZEC ownership.
How strong are liquidity, cash flow, and capital structure?
Cypherpunk has little conventional leverage, but liquidity risk remains. At March 31, 2026, liabilities were $3.003 million and cash was $6.689 million; most current assets were ZEC. Selling tokens could conflict with accumulation goals and expose the company to adverse prices and taxes.
| Financial measure | FY2025 | Q1 2026 / March 31, 2026 | Research interpretation |
|---|---|---|---|
| Cash and cash equivalents | $14.035M at Dec. 31, 2025 | $6.689M | Liquid cash fell $7.346M during Q1. |
| Digital assets receivable | $147.404M | $73.849M | Quarter-end ZEC price drove the sharp decline. |
| Operating cash flow | $(43.902)M | $(3.430)M for Q1 | Cash burn improved after the clinical wind-down. |
| Investing cash flow | $(97.000)M | $(9.000)M for Q1 | Capital deployment reflects ZEC purchases and the ZODL investment. |
| Financing cash flow | $107.649M | $5.075M for Q1 | External capital remains essential to the treasury strategy. |
| Net income or loss | $4.822M income | $(77.166)M loss | Both periods were dominated by unrealized ZEC valuation changes. |
What did FY2025 really show?
FY2025 R&D expense was $25.7 million, down from $57.2 million in FY2024, while G&A expense was $10.9 million, down from $12.8 million. Cash used in operations remained substantial because much of the clinical wind-down occurred during the year. The Q1 2026 cash-use rate is more representative of the reduced cost base, although stock compensation, public-company expenses, investment activity, and any renewed biotech development can change it.
How does capital allocation affect per-share value?
Equity, warrants, and an at-the-market program can finance purchases; the ATM agent earns 1.5% of gross sales. Capital is accretive only when asset value rises faster than dilution. Q1 weighted-average shares were 168.1 million for EPS purposes versus 93.9 million issued common shares at March 31, so models must include warrants, RSUs, and future issuance.
Who owns Cypherpunk stock, and how is it governed?
Ownership matters because the lead investor has a large stake and board-designation rights. The 2026 proxy, based on 97,678,728 shares at April 20, identified Winklevoss Capital Fund at 19.9% and Sean Michael Severins at 6.1%.
| Holder or group | Beneficial ownership | Ownership percentage | Why it matters |
|---|---|---|---|
| Winklevoss Capital Fund, LLC | 19,438,066 shares | 19.9% | Lead investor; affiliated entities share voting and investment power, subject to a 19.99% beneficial-ownership limitation. |
| Sean Michael Severins | 6,000,000 shares | 6.1% | Second disclosed holder above 5% in the 2026 proxy. |
| Directors and executive officers as a group | 3,515,474 shares | 3.5% | Insider economic ownership is meaningful but smaller than the lead investor’s stake. |
| Douglas E. Onsi | 707,922 shares | Less than 1% | CEO, CFO, general counsel, treasurer, and secretary roles are concentrated in one executive. |
The 2026 proxy statement also shows one vote per common share. Under the lead-investor agreement, Winklevoss Capital can designate two directors while it owns at least 16.7% and one director, who also serves as chair, while it owns at least 8.33% but below 16.7%. Khing Oei became chairman and Will McEvoy became chief investment officer and a director as part of the strategic transition.
Stockholders elected Will McEvoy and Nissim Mashiach at the June 18, 2026 annual meeting. The official annual-meeting voting results recorded 24,927,307 votes for McEvoy and 22,174,332 for Mashiach.
Which KPIs, opportunities, and risks matter most?
The key indicators are ZEC per diluted share, token value, cash runway, custody quality, financing terms, and non-ZEC investment value. Leap’s regulatory and partnering milestones are secondary but potentially material.
Which KPIs should researchers monitor?
| Risk or opportunity | Current evidence | Financial line affected | What to watch next |
|---|---|---|---|
| ZEC appreciation | 314,185.70 ZEC held at May 13, 2026 | Digital assets receivable, unrealized gain/loss, equity | Quarter-end token price and additional purchases |
| Custody concentration | ZEC trading and custody rely on Gemini infrastructure | Asset recoverability and operational continuity | Custodian diversification, controls, and disclosures |
| Financing and dilution | Equity, pre-funded warrants, common warrants, and ATM capacity | Cash, paid-in capital, diluted shares | ZEC acquired per incremental diluted share |
| Nasdaq compliance | Nasdaq compliance restored on May 21, 2026 after a March deficiency notice | Listing status and financing access | Continued compliance with Nasdaq listing standards |
| Internal control | Material weakness remained unremediated at March 31, 2026 | Reporting reliability and audit costs | Control remediation over complex digital-asset transactions |
| Biotech optionality | Fast Track designation and DKK1-high DeFianCe data | R&D expense, partnering income, future milestones | Partnering strategy and required development capital |
Which risks are most company-specific?
In 2025, ZEC traded between about $26.14 and $736.51. Custody is concentrated with Gemini, an affiliate of the lead investor, without FDIC or SIPC protection. A material weakness over complex transactions remained unremediated at March 31, 2026.
Nasdaq found in March 2026 that the shares had traded below the $1.00 minimum bid for 30 consecutive business days. Cypherpunk subsequently regained compliance on May 21, 2026, and Nasdaq closed the matter, according to the May 2026 compliance filing. The episode still illustrates how share-price volatility can affect listing access and financing flexibility.
Why is Cypherpunk unusual in a valuation model?
A standard DCF needs revenue and operating cash flow, which Cypherpunk lacks. A better framework separates marked-to-market ZEC, other investments, and probability-weighted biotech value, then subtracts liabilities and expected cash burn. This is adjusted net asset value with optionality.
| Valuation component | Primary driver | Key adjustment | Main sensitivity |
|---|---|---|---|
| ZEC treasury | Tokens held multiplied by current ZEC price | Custody, tax, liquidity, and corporate-structure discount or premium | Token price and ZEC per diluted share |
| Privacy-tech investments | Fair value of ZODL and future portfolio assets | Illiquidity and limited disclosure | Adoption, financing rounds, and exit probability |
| Leap Therapeutics | Probability-adjusted future licensing or product cash flow | Clinical, regulatory, financing, and commercialization risk | Partnering terms and development milestones |
| Corporate layer | Cash, liabilities, overhead, and future financing | Present value of cash burn and expected dilution | Capital-market access and management discipline |
What determines whether the stock deserves a premium or discount?
A premium requires accretive financing, rising ZEC per diluted share, valuable investments, and controlled overhead. Dilution, custody concentration, listing risk, or cheaper direct ZEC exposure support a discount. Valuation should use current holdings and fully diluted shares, not historical earnings.
What is the key takeaway from Cypherpunk Technologies analysis?
Cypherpunk is a case study in transforming a small biotech into a digital-asset treasury and privacy platform. Its thesis is to accumulate ZEC, fund the ecosystem, retain oncology optionality, and use public-market access. The company’s official mission emphasizes technologies that protect human privacy on the internet, while its investor page centralizes reporting and treasury updates.
The central lesson is to separate economic exposure from accounting presentation. Q1 2026’s $77.2 million loss was mainly mark-to-market, while FY2025’s $4.8 million income did not establish recurring profitability. Cypherpunk is a changing portfolio of assets, governance rights, and financing claims, with upside from privacy adoption and risks from concentration, dilution, custody, and execution.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.